Literature DB >> 15878322

Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.

Taketoshi Furugohri1, Yoko Shiozaki, Sumie Muramatsu, Yuko Honda, Chikako Matsumoto, Koji Isobe, Nobutoshi Sugiyama.   

Abstract

We compared the antithrombotic properties of a factor Xa inhibitor (DX-9065a) with those of a thrombin inhibitor (melagatran) in a rat disseminated intravascular coagulation model and a rat venous thrombosis model. Rat disseminated intravascular coagulation and venous thrombosis models were produced by injection of tissue factor and platinum wire placement, respectively. DX-9065a exerted antithrombotic effects dose dependently in both models. Melagatran was also effective in the venous thrombosis model, whereas it showed an aggravation in the disseminated intravascular coagulation model at low but not high doses. In the in vitro study, DX-9065a decreased the C(max) of the thrombin generation curve in plasma irrespective of whether protein C was present or not. However, melagatran increased the C(max) at low concentrations when protein C was present. This increase was not detected in protein C-deficient plasma. These results suggest that, unlike DX-9065a, melagatran in low doses aggravates disseminated intravascular coagulation by increasing thrombin generation, which may be partly due to suppression of negative feedback by activated protein C.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15878322     DOI: 10.1016/j.ejphar.2005.03.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.

Authors:  Elisabeth Perzborn; Susanne Roehrig; Alexander Straub; Dagmar Kubitza; Frank Misselwitz
Journal:  Nat Rev Drug Discov       Date:  2010-12-17       Impact factor: 84.694

Review 2.  Structure-function relationships of factor Xa inhibitors: implications for the practicing clinician.

Authors:  Benjamin A Steinberg; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

Review 3.  Current and future management of pediatric venous thromboembolism.

Authors:  Bryce A Kerlin
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

4.  Disease Severity Correlates with Thrombotic Capacity in Experimental Nephrotic Syndrome.

Authors:  Bryce A Kerlin; Amanda P Waller; Ruchika Sharma; Melinda A Chanley; Marvin T Nieman; William E Smoyer
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

Review 5.  The emerging role of coagulation proteases in kidney disease.

Authors:  Thati Madhusudhan; Bryce A Kerlin; Berend Isermann
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

6.  Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.

Authors:  Ihsan Gadi; Sameen Fatima; Berend Isermann; Khurrum Shahzad; Ahmed Elwakiel; Sumra Nazir; Moh'd Mohanad Al-Dabet; Rajiv Rana; Fabian Bock; Jayakumar Manoharan; Dheerendra Gupta; Ronald Biemann; Bernhard Nieswandt; Ruediger Braun-Dullaeus; Christian Besler; Markus Scholz; Robert Geffers; John H Griffin; Charles T Esmon; Shrey Kohli
Journal:  Circ Res       Date:  2020-12-23       Impact factor: 17.367

7.  Newer antithrombotic drugs.

Authors:  Pranav Sikka; V K Bindra
Journal:  Indian J Crit Care Med       Date:  2010-10

8.  Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.

Authors:  E Perzborn; S Heitmeier; U Buetehorn; V Laux
Journal:  J Thromb Haemost       Date:  2014-06-19       Impact factor: 5.824

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.